Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.-Reference-Cited by-同舟云学术

Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:5030-5030
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Antonarakis Emmanuel S.¹,Kibel Adam S.²,Adams George W.³,Karsh Lawrence Ivan⁴,Elfiky Aymen⁵,Shore Neal D.⁶,Vogelzang Nicholas J.⁷,Corman John M.⁸,Maher Johnathan Cartwright⁹,DeVries Todd⁹,McCoy Candice⁹,Sheikh Nadeem A.⁹,Drake Charles G.¹⁰

Affiliation:

1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

2. Brigham and Women's Hospital, Harvard University, Urologic Surgery, Boston, MA

3. Urology Centers of Alabama, Urology, Homewood, AL

4. The Urology Center of Colorado, Clinical Research, Denver, CO

5. Dana-Farber Cancer Institute, Boston, MA

6. Carolina Urologic Research Center, Myrtle Beach, SC

7. US Oncology Research Comprehensive Cancer Centers of Nevada, Las Vegas, NV

8. Virginia Mason Hospital & Seattle Medical Center, Seattle, WA

9. Dendreon Corporation, Seattle, WA

10. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Oncology, Baltimore, MD

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.5030

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens;JNCI: Journal of the National Cancer Institute;2021-02-25

2. Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth;Translational Oncology;2020-12

3. Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth;2020-05-09

4. Size-Based Enrichment Technologies for Non-cancerous Tumor-Derived Cells in Blood;Trends in Biotechnology;2018-05

5. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment;JNCI: Journal of the National Cancer Institute;2017-02-10